Issue: April 2017
April 06, 2017
1 min read
Save

Trial Scorecard: OSLER-1

Issue: April 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Extension study of safety and efficacy of evolocumab (Repatha, Amgen) in patients with hyperlipidemia at 4 years.

Trial Scorecard: OSLER-1